We have located links that may give you full text access.
Limited prognostic value of dual time point F-18 FDG PET/CT in patients with early stage (stage I & II) non-small cell lung cancer (NSCLC).
Radiotherapy and Oncology 2011 January
OBJECTIVE: The aim of the current study was to investigate the prognostic value of dual time point F-18 FDG PET/CT in patients with early stage (stage I & II) NSCLC.
METHODS: A retrospective review identified 66 patients with surgically resected early (stage I & II) NSCLC who received dual time point F-18 FDG PET/CT at diagnosis of cancer. Survival analysis was conducted using Kaplan-Meier analysis, and survival curves stratified by age, sex, mediastinal lymph node involvement, TNM staging, SUV(maxE), SUV(maxD), and %ΔSUV(max) were generated for estimation of overall survival and disease-free survival (DFS). Independent predictive factors for survival were determined using Cox proportional hazard model.
RESULTS: The overall survival and DFS were better in patients with tumor SUV(maxE)≤5.75 than the patients with tumor SUV(maxE)≥5.75. Seventeen patients (18.2%) with a tumor SUV(maxD)≥6.8 and 4 of 33 patients with tumor SUV(maxD)≤6.8 recurred during follow-up period. The median disease-free survival of the patients with tumor SUV(maxD)≥6.8 was 31.7 months and was significantly worse than the patients with tumor SUV(maxD)≤6.8 (Log rank test, Χ(2)=10.45, p=0.0012). The %ΔSUV(max) did not have prognostic values for overall survival and disease-free survival. The SUV(maxE) and SUV(maxD) were the potent predictors for overall survival. Also, the potent predictor of DFS was the SUV(maxE).
CONCLUSION: In conclusion, %ΔSUV(max) measured by dual time point F-18 FDG PET/CT might not have a prognostic value for overall survival and DFS in surgically resected early stage (stage I & II) NSCLC.
METHODS: A retrospective review identified 66 patients with surgically resected early (stage I & II) NSCLC who received dual time point F-18 FDG PET/CT at diagnosis of cancer. Survival analysis was conducted using Kaplan-Meier analysis, and survival curves stratified by age, sex, mediastinal lymph node involvement, TNM staging, SUV(maxE), SUV(maxD), and %ΔSUV(max) were generated for estimation of overall survival and disease-free survival (DFS). Independent predictive factors for survival were determined using Cox proportional hazard model.
RESULTS: The overall survival and DFS were better in patients with tumor SUV(maxE)≤5.75 than the patients with tumor SUV(maxE)≥5.75. Seventeen patients (18.2%) with a tumor SUV(maxD)≥6.8 and 4 of 33 patients with tumor SUV(maxD)≤6.8 recurred during follow-up period. The median disease-free survival of the patients with tumor SUV(maxD)≥6.8 was 31.7 months and was significantly worse than the patients with tumor SUV(maxD)≤6.8 (Log rank test, Χ(2)=10.45, p=0.0012). The %ΔSUV(max) did not have prognostic values for overall survival and disease-free survival. The SUV(maxE) and SUV(maxD) were the potent predictors for overall survival. Also, the potent predictor of DFS was the SUV(maxE).
CONCLUSION: In conclusion, %ΔSUV(max) measured by dual time point F-18 FDG PET/CT might not have a prognostic value for overall survival and DFS in surgically resected early stage (stage I & II) NSCLC.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices 
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app